These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29922710)

  • 21. Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies.
    Barnard ME; Poole EM; Curhan GC; Eliassen AH; Rosner BA; Terry KL; Tworoger SS
    JAMA Oncol; 2018 Dec; 4(12):1675-1682. PubMed ID: 30286239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Dickinson HO
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Dickinson HO
    Cochrane Database Syst Rev; 2009 Jul; (3):CD004706. PubMed ID: 19588360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.
    Schwartz PE; Rutherford TJ; Chambers JT; Kohorn EI; Thiel RP
    Gynecol Oncol; 1999 Jan; 72(1):93-9. PubMed ID: 9889037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
    Liutkauskiene S; Janciauskiene R; Jureniene K; Grizas S; Malonyte R; Juozaityte E
    BMC Cancer; 2015 Mar; 15():105. PubMed ID: 25879527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary.
    Kajiyama H; Suzuki S; Yoshikawa N; Kawai M; Shibata K; Nagasaka T; Kikkawa F
    Int J Gynecol Cancer; 2019 Jun; 29(5):910-915. PubMed ID: 30839284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Cancer; 1996 Nov; 78(10):2157-63. PubMed ID: 8918409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity-associated adipokines correlate with survival in epithelial ovarian cancer.
    Diaz ES; Karlan BY; Li AJ
    Gynecol Oncol; 2013 May; 129(2):353-7. PubMed ID: 23402904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Association of Aspirin Use with Survival Following Radical Cystectomy.
    Lyon TD; Frank I; Shah PH; Tarrell R; Cheville JC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    J Urol; 2018 Nov; 200(5):1014-1021. PubMed ID: 29857079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.
    Strasser-Weippl K; Higgins MJ; Chapman JW; Ingle JN; Sledge GW; Budd GT; Ellis MJ; Pritchard KI; Clemons MJ; Badovinac-Crnjevic T; Han L; Gelmon KA; Rabaglio M; Elliott C; Shepherd LE; Goss PE
    J Natl Cancer Inst; 2018 Sep; 110(9):1003-1008. PubMed ID: 29554282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 40. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
    Karam AK; Santillan A; Bristow RE; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Li AJ
    Gynecol Oncol; 2007 Feb; 104(2):377-80. PubMed ID: 17014899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.